Posted by Michael Wonder on 03 Nov 2020
ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the marketing authorisation application for avacopan
3 November 2020 - Regulatory submission based on positive data from the pivotal Phase 3 ADVOCATE trial of avacopan.
Vifor Fresenius Medical Care Renal Pharma and ChemoCentryx today announced that the EMA accepted to review the marketing authorisation application for avacopan for the treatment of patients with ANCA associated vasculitis (granulomatosis with polyangitis and microscopic polyangiitis), a group of rare and severe autoimmune diseases with high need for targeted therapies.
